19 results match your criteria covid-19 fluvoxamine

  • Page 1 of 1

Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?

Folia Neuropathol 2021 ;59(2):113-120

Department of Neurology, Medical University of Lublin, Lublin, Poland.

The majority of COVID-19 cases are only mildly or moderately symptomatic, but in some patients excessive inflammatory response becomes the dominant factor of disease progression to the advanced stage, with high mortality. Treatment with anti-inflammatory drugs either does not prevent disease progression (non-steroidal anti-inflammatory drugs [NSAIDs], colchicine), or is recommended only at the advanced disease stage (dexamethasone). Fluvoxamine and amantadine are drugs used to treat neurological and psychiatric diseases. Read More

View Article and Full-Text PDF

Pharmacological Treatment of Patients with Mild to Moderate COVID-19: A Comprehensive Review.

Int J Environ Res Public Health 2021 07 5;18(13). Epub 2021 Jul 5.

Department of Medicine, University of Ribeirão Preto, 2201 Costabile Romano, Ribeirão Preto 14096-385, Brazil.

Mild to moderate COVID-19 can be found in about 80% of patients. Although mortality is low, mild to moderate COVID-19 may progress to severe or even critical stages in about one week. This poses a substantial burden on the health care system, and ultimately culminates in death or incapacitation and hospitalization. Read More

View Article and Full-Text PDF

Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy.

Expert Opin Ther Targets 2021 Jul 15:1-15. Epub 2021 Jul 15.

Natural Products for Neuroprotection and Anti-ageing Research Unit, Chulalongkorn University, Bangkok, Thailand.

: Despite the availability of new vaccines for SARS-CoV-2, there has been slow uptake and problems with supply in some parts of the world. Hence, there is still a necessity for drugs that can prevent hospitalization of patients and reduce the strain on health care systems. Drugs with sigma affinity potentially provide protection against the most severe symptoms of SARS-COV-2 and could prevent mortality via interactions with the sigma-1 receptor. Read More

View Article and Full-Text PDF

Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review.

Ann Pharmacother 2021 Jun 22:10600280211028242. Epub 2021 Jun 22.

Health Information and Quality Authority, Dublin, Ireland.

Objective: To conduct a systematic review on the effectiveness and safety of pharmacological and nonpharmacological interventions, in the ambulatory setting, aimed at preventing severe disease in patients with COVID-19.

Data Sources: Electronic databases (PubMed, EMBASE, and EuropePMC) were searched on January 6, 2021.

Study Selection And Data Extraction: A systematic review was conducted, adhering to PRISMA guidelines. Read More

View Article and Full-Text PDF

Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective.

Environ Anal Health Toxicol 2021 Jun 14;36(2):e2021010-0. Epub 2021 Jun 14.

Department of Chemistry, Imo State University, Owerri, PMB 2000 Owerri, Imo State, Nigeria.

The coronavirus disease of 2019 (COVID-19) has become a global pandemic with rapid rate of transmission and fatalities worldwide. Scientists have been investigating a host of drugs that may be rechanneled to fight this malaise. Thus, in this current computational study we carried out molecular docking experiments to assess the bridging potentials of some commercial drugs such as chloroquine, hydroxychloroquine, lopinavir, ritonavir, nafamostat, camostat, famotidine, umifenovir, nitazoxanide, ivermectin, and fluvoxamine at the interface between human ACE2 and the coronavirus spike glycoprotein complex. Read More

View Article and Full-Text PDF

Fluvoxamine for COVID-19?


Med Lett Drugs Ther 2021 05;63(1623):69-70

View Article and Full-Text PDF

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19.

Front Pharmacol 2021 20;12:652688. Epub 2021 Apr 20.

GlobalCures, Inc., Newton, MA, United States.

Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized study to prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19). Fluvoxamine is also an agonist for the sigma-1 receptor, through which it controls inflammation. We review here a body of literature that shows important mechanisms of action of fluvoxamine and other SSRIs that could play a role in COVID-19 treatment. Read More

View Article and Full-Text PDF

Remote Research and Clinical Trial Integrity During and After the Coronavirus Pandemic.

JAMA 2021 05;325(19):1935-1936

Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.

View Article and Full-Text PDF

The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19.

Comput Biol Chem 2021 Jun 5;92:107482. Epub 2021 Apr 5.

Chemical Biology Laboratory, School of Basic Sciences, Indian Institute of Technology Bhubaneswar, Odisha, 752050, India. Electronic address:

Complement system plays a dual role; physiological as well as pathophysiological. While physiological role protects the host, pathophysiological role can substantially harm the host, by triggering several hyper-inflammatory pathways, referred as "hypercytokinaemia". Emerging clinical evidence suggests that exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), tricks the complement to aberrantly activate the "hypercytokinaemia" loop, which significantly contributes to the severity of the COVID19. Read More

View Article and Full-Text PDF

Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19?

Pharmacopsychiatry 2021 05 17;54(3):142-143. Epub 2021 Mar 17.

Department of Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, Germany.

View Article and Full-Text PDF

Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.

Int J Mol Sci 2021 Feb 11;22(4). Epub 2021 Feb 11.

Institute of Precision Medicine, Medical and Life Sciences Faculty, Furtwangen University, Jakob-Kienzle-Str. 17, D-78054 Villingen-Schwenningen, Germany.

Lysosomotropism is a biological characteristic of small molecules, independently present of their intrinsic pharmacological effects. Lysosomotropic compounds, in general, affect various targets, such as lipid second messengers originating from lysosomal enzymes promoting endothelial stress response in systemic inflammation; inflammatory messengers, such as IL-6; and cathepsin L-dependent viral entry into host cells. This heterogeneous group of drugs and active metabolites comprise various promising candidates with more favorable drug profiles than initially considered (hydroxy) chloroquine in prophylaxis and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections/Coronavirus disease 2019 (COVID-19) and cytokine release syndrome (CRS) triggered by bacterial or viral infections. Read More

View Article and Full-Text PDF
February 2021

Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?

Croat Med J 2021 02;62(1):95-100

Robert Likić, University of Zagreb School of Medicine, Zagreb, Croatia,

View Article and Full-Text PDF
February 2021

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.

Open Forum Infect Dis 2021 Feb 1;8(2):ofab050. Epub 2021 Feb 1.

University of Minnesota Medical School, Minneapolis, Minnesota, USA.

We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12. Read More

View Article and Full-Text PDF
February 2021

Homozygosity for rs17775810 Minor Allele Associated With Reduced Mortality of COVID-19 in the UK Biobank Cohort.

In Vivo 2021 Mar-Apr;35(2):965-968

Severn Health Solutions, Severna Park, MD, U.S.A.

Background/aim: Adult outpatients with symptomatic COVID-19 treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days. Fluvoxamine strongly binds to the sigma-1 receptor (S1R) that regulates inflammation by inhibiting the production of cytokines, believed to be responsible for severe COVID-19. We evaluated the S1R locus on chr 9p13. Read More

View Article and Full-Text PDF

Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor.

Kenji Hashimoto

Eur Arch Psychiatry Clin Neurosci 2021 Mar 5;271(2):249-258. Epub 2021 Jan 5.

Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba, 260-8670, Japan.

The novel coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The escalating number of SARS-CoV-2-infected individuals has conferred the viral spread with the status of global pandemic. However, there are no prophylactic or therapeutic drugs available on the market to treat COVID-19, although several drugs have been approved. Read More

View Article and Full-Text PDF

Fluvoxamine, melatonin and COVID-19.

Psychopharmacology (Berl) 2021 02 4;238(2):611. Epub 2021 Jan 4.

Child Study Center and the Department of Laboratory Medicine, Yale University School of Medicine, 230 S. Frontage Rd., New Haven, CT, 06525, USA.

View Article and Full-Text PDF
February 2021

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.

JAMA 2020 12;324(22):2292-2300

Department of Psychiatry, School of Medicine, Washington University in St Louis, St Louis, Missouri.

Importance: Coronavirus disease 2019 (COVID-19) may lead to serious illness as a result of an excessive immune response. Fluvoxamine may prevent clinical deterioration by stimulating the σ-1 receptor, which regulates cytokine production.

Objective: To determine whether fluvoxamine, given during mild COVID-19 illness, prevents clinical deterioration and decreases the severity of disease. Read More

View Article and Full-Text PDF
December 2020

A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.

Trials 2020 Jun 3;21(1):466. Epub 2020 Jun 3.

Clinical Pharmacology Department, Clinical Trial Unit, La Paz University Hospital - IdiPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.

Objectives: Primary objective: to evaluate the efficacy of melatonin as a prophylactic treatment on prevention of symptomatic SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 exposure. Secondary objectives: To evaluate the efficacy of melatonin as a prophylactic treatment on prevention of asymptomatic SARS-CoV-2 infection.To evaluate the efficacy of melatonin to prevent the development of severe COVID-19 in the participants enrolled in this study who develop SARS-CoV-2 infection along the trial. Read More

View Article and Full-Text PDF
  • Page 1 of 1